Inappropriate activation of Toll-like receptor 4 (TLR4) on resident fibroblasts, through the binding of damage-associated molecular patterns, is a potential driver of fibrosis in systemic sclerosis. New evidence suggests that targeting fibroblast-specific TLR4 or an accessory molecule MD2 could have therapeutic value.
CITATION STYLE
O’reilly, S., & van Laar, J. M. (2018). Targeting the TLR4–MD2 axis in systemic sclerosis. Nature Reviews Rheumatology, 14(10), 564–566. https://doi.org/10.1038/s41584-018-0077-6
Mendeley helps you to discover research relevant for your work.